company background image
RAC logo

Race Oncology CHIA:RAC Stock Report

Last Price

AU$1.38

Market Cap

AU$240.4m

7D

-0.7%

1Y

73.6%

Updated

17 Dec, 2024

Data

Company Financials +

Race Oncology Limited

CHIA:RAC Stock Report

Market Cap: AU$240.4m

RAC Stock Overview

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. More details

RAC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 34.81% per year

Risk Analysis

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (A$4M)


My Notes

Capture your thoughts, links and company narrative

Race Oncology Limited Competitors

Orthocell

ASX:OCC

AU$274.0m

Aroa Biosurgery

ASX:ARX

AU$224.2m

Actinogen Medical

ASX:ACW

AU$86.1m

Imugene

ASX:IMU

AU$275.2m

Price History & Performance

Summary of share price highs, lows and changes for Race Oncology
Historical stock prices
Current Share PriceAU$1.38
52 Week HighAU$2.09
52 Week LowAU$0.64
Beta1.83
1 Month Change-4.50%
3 Month Change-17.86%
1 Year Change73.58%
3 Year Change-57.28%
5 Year Change645.95%
Change since IPO441.18%

Recent News & Updates

Recent updates

Shareholder Returns

RACAU BiotechsAU Market
7D-0.7%-0.8%-1.0%
1Y73.6%3.9%9.8%

Return vs Industry: RAC exceeded the Australian Biotechs industry which returned 3.7% over the past year.

Return vs Market: RAC exceeded the Australian Market which returned 10% over the past year.

Price Volatility

Is RAC's price volatile compared to industry and market?
RAC volatility
RAC Average Weekly Movement6.6%
Biotechs Industry Average Movement9.4%
Market Average Movement8.1%
10% most volatile stocks in AU Market16.9%
10% least volatile stocks in AU Market3.1%

Stable Share Price: RAC has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: RAC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aDaniel Tillettwww.raceoncology.com

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.

Race Oncology Limited Fundamentals Summary

How do Race Oncology's earnings and revenue compare to its market cap?
RAC fundamental statistics
Market capAU$240.37m
Earnings (TTM)-AU$13.82m
Revenue (TTM)AU$4.00m

60.0x

P/S Ratio

-17.4x

P/E Ratio

Is RAC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RAC income statement (TTM)
RevenueAU$4.00m
Cost of RevenueAU$2.61m
Gross ProfitAU$1.39m
Other ExpensesAU$15.21m
Earnings-AU$13.82m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.081
Gross Margin34.72%
Net Profit Margin-345.18%
Debt/Equity Ratio0%

How did RAC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 00:19
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Race Oncology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullIndependent Investment Research (Aust.) Pty Ltd
Chris KallosMST Financial Services Pty Limited